After years as both an actor and a screenwriter, Cliff Dorfman is ready to set the stage for the next phase of his Hollywood career with his most personal project to date.
Dorfman, 58, rose to prominence in the 1990s with supporting roles on "Beverly Hills, 90210," among other shows. After shifting his focus to screenwriting, he wrote 14 episodes of HBO's "Entourage" and co-wrote the screenplay for the 2011 feature film "Warrior," starring Tom Hardy.
Buzz: Jameela Jamil Declares Botox A 'Prison' For Women: 'We Have Lost A Grip On Reality'
Despite those accomplishments, Dorfman says, he never had a chance to "understand my own story — and to survive it" until he wrote "Crime Family," his debut novel. Published in July, the 287-page thriller follows Chase Forman, a Hollywood writer who returns to his native Long Island, New York, to **** ist his family as his adoptive father's health and mental acuity decline.
Though Chase has spent most of his adulthood distancing himself from the Formans, he soon discovers that his family is part of an organized crime empire, with his adoptive mother, Helene, personally overseeing an international money-laundering operation. What follows is a gripping bicoastal chase as Chase and his family members become fugitives on the run from the FBI.

#family #dorfman #adoptive #cliff

For years now, fans of Oscar-winning actress Jennifer Lawrence have speculated that she underwent plastic surgery to enhance her ageless looks, with many believing that she had an entire facelift done.
Jennifer finally admitted to the cosmetic enhancements she had received over the years and shared the one procedure she would never dare to do.
Jennifer shared that she had received baby Botox in the past (@ Penske Media via Getty Images)
"I need to have movement in my face," the star told Vogue. "I get baby Botox, but I can't do a lot. If my skin is going to be a little saggier than I would like, at least it looks dewy and pretty."
Jennifer explained that she wanted to undergo a buccal fat removal procedure, which occurs when the fat pads from the lower cheeks are removed from the face to make it appear slimmer. "I would love to have a buccal fat removal. I can't because everybody would know, but just know that I want that," she said.

#looks #shared

For years, AbbVie (NYSE: ABBV) was known primarily for immunology. Humira built the company into a pharmaceutical giant, and newer blockbusters Skyrizi and Rinvoq have helped replace much of the revenue lost to biosimilar competition. Now the company's got another iron in the fire -- neuroscience -- and it's no slouch.
Management now expects its neuroscience portfolio to generate approximately $12.7 billion in revenue during 2026, raising guidance by another $100 million after a strong first half of the year. That's a remarkable figure when you consider that the portfolio generated $10.8 billion last year and continues to grow at a double-digit pace.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Unlike some pharmaceutical franchises that depend on a single blockbuster, AbbVie's neuroscience business has become increasingly diversified. During the second quarter, neuroscience revenue climbed 20.3% year over year to $3.23 billion. Schizophrenia and bipolar disorder drug Vraylar generated $1.07 billion, therapeutic Botox contributed $1.04 billion, and migraine drugs Ubrelvy and Qulipta combined for $742 million in quarterly sales. Parkinson's disease therapy Vyalev added another $256 million.
The fastest-growing part of AbbVie's neuroscience business may be migraine. Combined sales rose 22.6% year over year as Ubrelvy and Qulipta continued gaining traction with physicians addressing both acute migraine attacks and migraine prevention.

#year #billion #revenue #million

AbbVie Inc. (NYSE:ABBV) reported its first-quarter 2026 financial results, delivering worldwide net revenues of $15.002 billion, an increase of 12.4% on a reported basis (10.3% operationally). The company posted GAAP diluted EPS of $0.39 and adjusted diluted EPS of $2.65, which exceeded internal expectations despite including a $0.41 per share unfavorable impact from acquired IPR&D and milestone expenses. Grounded in this solid operational momentum, ABBV raised its full-year 2026 adjusted diluted EPS guidance range to $14.08–$14.28.
Adding to its commercial trajectory, AbbVie's Allergan Aesthetics announced on July 17 that the European Commission approved Boey (trenibotulinumtoxinE) across all 30 European Economic Area countries. Marked as the first and only rapid-onset, short-duration botulinum neurotoxin serotype E in Europe, Boey targets the temporary improvement of moderate to severe frown lines with an onset as fast as eight hours and results lasting two to three weeks. This regulatory milestone follows approval in Canada earlier in the year and expands AbbVie's high-margin aesthetic portfolio beyond traditional Botox offerings.
Following these catalysts, Wall Street **** yst revisions have turned increasingly positive. On July 22, Canaccord raised its price target on AbbVie to $282 from $273 while maintaining a Buy rating. The firm updated its financial model ahead of Q2 earnings, citing expected strength across core prescription volume trends and recent positive developmental wins.
This momentum brings up a pivotal question: Does AbbVie's successful pivot away from legacy reliance justify higher valuation multiples, or do long-term debt levels and margin pressures cap future upside?
Proponents of the bullish case emphasize AbbVie Inc. (NYSE:ABBV)'s high-performing post-Humira growth engine. Top-line expansion is overwhelmingly driven by its flagship immunology **** ets, Skyrizi and Rinvoq, which generated $4.483 billion (+30.9% reported) and $2.119 billion (+23.3% reported) in Q1 net revenues, respectively. Rapid, durable share gains across multiple indication rollouts highlight a strong product-market fit that effectively absorbs legacy biosimilar erosion.

#diluted

AbbVie (NYSE:ABBV) just moved a step closer to expanding one of its most recognizable brands. On August 4, the FDA accepted for review a supplemental Biologics License Application for Botox Cosmetic to treat masseter muscle prominence, the jaw-muscle bulge that can give a face a wider, squarer look. If cleared, Botox Cosmetic would become the first and only neurotoxin approved for that use in the US and the fifth aesthetic indication for a drug that already anchors AbbVie's fastest-growing units.
The filing rests on two Phase 3 studies, M21-416 and M21-417, both of which hit their main goal and showed statistically significant improvement in masseter prominence against a placebo, with p-values of 0.0046 and 0.0014. Twice as many treated patients called themselves satisfied compared with the placebo group, and the safety data lined up with Botox's long track record, with no new red flags. That is the AbbVie playbook in miniature: squeeze another approved use out of a drug it already owns rather than starting from zero.
The broader business backs that pattern up. In the quarter ended June 30, net revenue came in just under $17 billion, up more than 10% year over year, with immunology sales climbing 15% on Skyrizi and Rinvoq and neuroscience revenue jumping more than 20%. Management raised its full-year outlook for the second time this year, and the Humira patent-cliff drag that weighed on results for two years now looks largely behind the company.
Most of AbbVie's US product sales still flow through just three wholesale distributors, McKesson, Cardinal Health, and Cencora, a concentration that leaves the company exposed if any one relationship sours. The balance sheet carries real leverage too: a debt-to-equity ratio of roughly -21.1x as of its December 2025 filing means liabilities outweigh shareholder equity outright, and a current ratio near 0.7x offers less short-term cushion than many healthcare peers hold.
Patent protection for Skyrizi and Rinvoq remains a multi-year risk, and the Inflation Reduction Act already allows government price negotiation on products including Imbruvica and, notably, Botox itself. The pending $10.9 billion Apogee Therapeutics acquisition adds fresh debt and integration risk on top of that. Oncology revenue slipped almost 2% in the latest quarter, and the stock's 8% gain this year has trailed the S&P 500's 13%, with a trailing P/E near 70 that mostly reflects acquisition-related charges rather than the underlying business.

#revenue

Britney Spears is warning fans to be careful with Botox after saying a recent cosmetic procedure left one of her eyes drooping for weeks.
The "Toxic" hitmaker, 44, took to Instagram on August 7, to share a video about her experience.
"Because he put so much Botox in this left eye that it drooped down like that," she said while pressing her fingers to her left eye. "And it's just now starting to raise up and be normal again. It's so embarrassing."
Spears urged anyone considering Botox to proceed with caution.
She added, "Girls, you have to be careful if you do Botox. These people and these doctors, they can really [expletive] your eyes up."

#careful

Britney Spears says a recent Botox treatment left her with a drooping eyelid for about four weeks, prompting her to warn followers to be careful with cosmetic injections.
The 44-year-old singer described the experience in an Instagram video, claiming too much Botox had been injected around her left eye. Spears demonstrated the effect by pressing down the skin above the eye and said it was only beginning to return to normal.
She called the result embarrassing and warned people considering Botox to be cautious about who performs the procedure. Spears captioned the video, "You can't trust anyone!!!" according to Page Six.
The experience follows several previous occasions when Spears publicly complained about unwanted results from Botox, including an eyebrow that remained raised for weeks and a later treatment she said caused swelling and drooping around her eyes.
Spears blamed the latest problem on what she believed was too much Botox around her left eye. "She put so much Botox in this left eye that it drooped down like that," Spears said, according to The Independent.

#botox #left #drooping

Bethenny Frankel opened up about how Botox "changed my face entirely" during a candid new interview
The reality star also shared her thoughts on other kinds of treatments, like lasers and hair extensions
Frankel previously told PEOPLE why she won't try facial fillers again
Bethenny Frankel is getting real about cosmetic procedures.
In an interview with NewBeauty published on Tuesday, July 28, the reality star, 55, said that Botox treatments have impacted her "tremendously."

#botox #interview #star

When it comes to dividend stocks, no other sector has been more reliable than the healthcare sector. No matter the economic scenario, there will always be demand for drugs treating life-threatening diseases. This keeps the sector defensive, allowing large pharmaceutical companies to generate steady cash flow and consistently reward shareholders.
Two pharmaceutical giants — AbbVie (ABBV) and Eli Lilly (LLY) — stand out for some of the fastest-growing drug portfolios in the industry. However, only one is the better choice for income-seeking investors. Let's take a closer look.
Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, ******* ysis, and headlines.
AbbVie is a global biopharmaceutical company that develops medicines for immunology, cancer, neuroscience, and aesthetics, with blockbuster drugs including Skyrizi, Rinvoq, and Botox. AbbVie's forward dividend yield of 2.65% is higher than the market and the healthcare sector average. This higher income compounds meaningfully over a decade, especially for investors who reinvest their dividends.
When AbbVie's top-selling drug, Humira, began losing patent protection, investors questioned whether it would weaken earnings and pressure dividends. However, the company has spent the last few years successfully replacing it, as Skyrizi and Rinvoq have become AbbVie's new growth engines, generating $6.6 billion in combined revenue in the first quarter of 2026.

We’ve been enjoying the nice weather in the garden on my day off today.
I’ve been hiding in the shade, resting after days of migraine pain with sleepless, vomitey nights…Must chase neurology about my overdue Botox for migraine jabs.
Daisy has been dozing in her favourite hebe!